Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced positive results from an exploratory Phase 2A study of PH284 in cancer cachexia. PH284 is an investigational pherine nasal spray differentiated from all current treatments for the loss of appetite associated with chronic disorders, such as cancer. In the study, PH284 demonstrated higher mean subjective feeling of hunger as compared to placebo and appeared safe and well-tolerated with an adverse event profile similar to placebo in a population compromised by terminal cancer.

Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in Phase 3 development for the acute treatment of social anxiety disorder (SAD).

Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Healthcare Conference taking place November 18 and 19, 2024 in New York City.

Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate update.

Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new prevalence data for social anxiety disorder (SAD), an indication for which fasedienol, its lead intranasal pherine product candidate, is in U.S. registration-directed Phase 3 development for the acute treatment of the disorder, and two additional non-systemic intranasal pherine product candidates in its neuroscience pipeline, itruvone in Phase 2 development for major depressive disorder and hormone-free PH80 in Phase 2 development for the management of vasomotor symptoms (hot flashes) due to menopause, at the 2024 Neuroscience Education Institute (NEI) Congress in Colorado Springs, Colorado from November 7 to 10, 2024.

Vistagen (NASDAQVTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter ended September 30, 2024, and provide a corporate update.

Vistagen (NASDAQVTGN) is a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. The company today announced that CEO Shawn Singh, The Goldie Hawn Foundation Founder Goldie Hawn, and children from New York City schools using The Goldie Hawn Foundation’s MindUp, a neuroscience-based preventative mental health program for youth, will jointly ring the Nasdaq Closing Bell on October 10, 2024. The joint ceremony will commemorate World Mental Health Day and The Goldie Hawn Foundation’s 20th Anniversary. The ceremony will highlight the power of collaboration and shared commitment to advance neuroscience-based innovation.

Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation’s MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join together in New York City on October 10, 2024 to ring the Nasdaq Closing Bell in honor of World Mental Health Day and The Goldie Hawn Foundation’s 20th Anniversary.

Vistagen (Nasdaq: VTGN) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in its PALISADE-4 Phase 3 trial of fasedienol, an investigational neuroactive pherine nasal spray in U.S. registration-directed Phase 3 development for the acute treatment of social anxiety disorder (SAD).

VTGN stock results show that VistaGen Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025.

Vistagen Therapeutics (NASDAQVTGN), a late clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, is reporting its financial results for the first quarter 2025, or the period ended June 30, 2024. The report also included a status update on the company’s pipeline, including fasedienol for the acute treatment of social anxiety disorder (“SAD”), itruvone for major depressive disorder (“MDD”) and PH80 for vasomotor symptoms, or hot flashes, due to menopause.

Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 first quarter ended June 30, 2024, and provided a corporate update.

Vistagen (NASDAQVTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, is announcing that it will host a conference call and webcast on Tuesday, August 13, 2024, at 2 p.m. PT (5 p.m. ET). During the call and webcast, the company will report results for the first quarter of its fiscal year 2025 ended June 30, 2024 (“Q1 2025”). In addition, Vistagen will provide a corporate update. Interested participants should dial 1-877-407-9716 (U.S. toll-free) or 1-201-493-6779 (toll/international) and enter the conference ID 13748020. Alternatively, partners can listen to the audio webcast of the conference call.

Vistagen (NASDAQVTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Tuesday, August 13, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 first quarter ended June 30, 2024 and provide a corporate update.

Investors looking for millionaire status in the coming years should consider three stocks under $15 that could be worth buying.

Vistagen Therapeutics (NASDAQVTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patents. According to the company, the new patents cover the use of PH80 for the treatment of migraine and represent a broadening of Vistagen’s global intellectual property portfolio. The patents have been issued from four different countries, including Australia, Hong Kong, Japan and Mexico. A nonsystemic, hormone-free investigational pherine nasal spray, PH80 is being developed as a rapid-onset treatment for hot flashes during menopause; the spray has also shown potential for treatment of premenstrual dysphoric disorder, dysmenorrhea and migraine. A novel class of synthetic neurocircuitry-focused drug candidates for psychiatric and neurological disorders, pherines are odorless and tasteless neuroactive steroids that offer a differentiated mechanism of action and safety profile from all currently approved drugs.

Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global intellectual property portfolio after receiving multiple new patents related to the use of PH80 for the treatment of migraine. PH80 is a non-systemic, hormone-free investigational pherine nasal spray in development as a rapid-onset treatment for vasomotor symptoms (hot flashes) due to menopause, with the potential to also treat premenstrual dysphoric disorder, dysmenorrhea, and migraine.

Vistagen (NASDAQVTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to promoting mental health and well-being in the workplace. This marks the second consecutive year the company has received this recognition. According to the announcement, Vistagen earned MHA’s highest honor, the Platinum Bell Seal for Workplace Mental Health, for its supportive workplace culture, mental health care benefits, emphasis on inclusion, and employee wellness programs. “Our mission and dedication to improving global mental health with groundbreaking therapies for anxiety, depression, and other psychiatric disorders starts with a collective team effort within our own organization and by prioritizing our employees’ mental health and well-being at work and beyond while we continue to make remarkable progress in our late clinical-stage neuropsychiatry programs. An essential element of our strategy is normalizing conversations about mental health and encouraging individuals to access our extensive support resources. This is an important time to highlight mental health. We are honored to have received Mental Health America’s 2024 Platinum Bell Seal for Workplace Mental Health. We thank MHA for once again recognizing our ongoing commitment to our team’s mental health,” said Shawn Singh, CEO of Vistagen.

Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, announced today that for the second consecutive year it has been recognized by Mental Health America (MHA) for its dedication to promoting mental health and well-being in the workplace. Vistagen’s supportive workplace culture, mental health care benefits, emphasis on inclusion, and employee wellness programs have earned it MHA’s highest honor, the Platinum Bell Seal for Workplace Mental Health.

VTGN stock results show that VistaGen Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.

Vistagen Therapeutics (NASDAQVTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, is reporting financial results for the fiscal year ended March 31, 2024; the report also included a corporate update. Highlights of the report included that Vistagen’s registration-directed fasedienol PALISADE phase 3 program for the acute treatment of social anxiety disorder is progressing on track and that its PALISADE-3 phase 3 trial has recently been initiated with plans for PALISADE-4 phase 3 trial initiation in the second half of 2024. Financial numbers reported included research and development expenses totaling $20 million and general and administrative expenses reaching $14.1 million, with a net loss for the year of $29.4 million, down from $59.2 million for FY 2023. The report also showed cash and cash equivalents of $119.2 million as of March 31, 2024, with 27,029,731 shares of common stock issued and 3,577,240 prefunded warrants outstanding as of June 10, 2024. “Vistagen’s fiscal 2024 proved to be a year full of remarkable accomplishments,” said Vistagen Therapeutics CEO Shawn Singh in the press release. “Most notably, with our PALISADE-2 trial of fasedienol, we became the first company to report positive results of a phase 3 trial for the acute treatment of social anxiety disorder, a mental-health disorder affecting the lives of over 30 million adults in the U.S for which there is no FDA-approved acute treatment option. In addition, we recently initiated our PALISADE-3 phase 3 trial, which, if successful, has the potential to complement PALISADE-2 in support of a fasedienol U.S. New Drug Application submission. Our primary focus is on the high-quality execution of our registration-directed PALISADE phase 3 program for fasedienol in social anxiety disorder, as well as the further progression of our nonsystemic, neurocircuitry-focused pherine development programs involving itruvone for major depressive disorder and hormone-free PH80 for menopausal hot flashes. We are well-positioned on a path toward achieving multiple potential value-creating catalysts during the year ahead as we pursue our mission to develop and commercialize differentiated neuroscience therapies to improve patients’ lives worldwide.”

Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year ended March 31, 2024, and provided a corporate update.

Vistagen (NASDAQVTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, plans to host a conference call and webcast on Tuesday, June 11, 2024, at 2 p.m. PT (5 p.m. ET). During the conference call, the company will report results for its fiscal year 2024 ended March 31, 2024, and provide a corporate update. Interested parties can dial 1-877-407-9716 (toll-free) or 1-201-493-6779 (international), then key in the conference ID 13746589.

Vistagen (NASDAQVTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, June 11, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 ended March 31, 2024 and provide a corporate update.

Vistagen (NASDAQVTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. The company has announced that its management will present and host one-on-one meetings during the Jefferies Global Healthcare Conference slated to take place in New York City on June 5 and 6, 2024. Vistagen’s Chief Executive Officer Shawn Singh will participate in a fireside chat on Thursday, June 6 at 11:00 a.m. Eastern Time. A webcast will be accessible through the events page of Vistagen’s website . Investors interested in scheduling a one-on-one meeting during the conference should contact their Jefferies representative.